Biotech Short Candidates Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

DewDiligence_on_SI

To: tuck who wrote (878)	12/13/2017 1:56:23 PM
From: tuck	1 Recommendation Read Replies (1) of 897

Actually added to my position on GALT this morning. Since the trial fail and spin, there has been no financing, despite the rebound. In light of this, the following snip from the latest quarterly report is very relevant: "As of September 30, 2017, the Company had $7.0 million of non-restricted cash and cash equivalents. The Company believes it has sufficient cash to fund currently planned operations and research and development activities through December 31, 2017." This for a company that is apparently planning on pursuing a late stage NASH trial, and has other earlier programs. And no partners. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next